Cizzle Biotechnology never a better time to invest in diagnostics (Interview)

Cizzle Biotechnology Holdings plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss the successful listing on to the Main Market of London Stock Exchange. Allan explains what the company does, how a blood test for the early detection of a majority of the different forms of lung cancer works, patents in place, how the proceeds will be utilised and how Allan views the outlook for the company.

Cizzle Biotechnology is a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Cizzle Biotech

    More articles like this

    Cizzle Biotech

    Cizzle Biotechnology AGM to be held on 27 June 2022

    Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, has announced that copies of the annual report and accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting, have been sent to shareholders and

    Hardman & Co

    Cizzle Biotechnology: Strategic alliance in China

    Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for a

    Hardman & Co

    Cizzle Biotechnology: News flow driven by deals

    Cizzle Biotechnology Holdings plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for early detection of different forms of lung cancer. There is high medical need for

    No more posts to show